You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 123 No. 10, October 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Clinical Sciences
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on ISI (2)
 •Contact me when this article is cited
 Related Content
 •Related letter
 •Similar articles in this journal
 Topic Collections
 •Choroidal Neovascularization
 •Macular Degeneration
 •Retinal/ Chorioretinal Disorders
 •Ophthalmological Procedures, Other
 •Articles for Residents
 •Alert me on articles by topic

Complications After Photodynamic Therapy

Ute E. K. Schnurrbusch, MD; Claudia Jochmann, MD; Wilma Einbock, MD; Sebastian Wolf, MD, PD

Arch Ophthalmol. 2005;123:1347-1350.

Objective  To evaluate the incidence of complications of photodynamic therapy (PDT) with verteporfin in subfoveal choroidal neovascularizations secondary to age-related macular degeneration and pathologic myopia.

Methods  In this retrospective interventional case series, the occurrence of complications after PDT in a clinical setting was analyzed. Consecutive medical records of patients with age-related macular degeneration and pathologic myopia treated with PDT were reviewed for complications. Complications included treatment-related systemic adverse events, injection site effects, and ocular adverse events.

Results  We included 273 patients (198 with age-related macular degeneration and 75 with pathologic myopia) in the study. A total of 485 photodynamic treatment sessions were performed. Infusion-related back or chest pain was reported by 6 patients (2.2%; 95% confidence interval [CI], 0.8%-4.7%). Injection site effects, extravasation, and photosensitivity reactions were not observed. Dyspnea and flushing during infusion were observed in 2 patients (0.7%; 95% CI, 0.09%-2.6%). Body pain, shortness of breath, and elevated blood pressure were noted in 13 patients (4.8%; 95% CI, 2.6%-8.0%). General pruritus was described by 6 patients (2.2%; 95% CI, 0.8%-4.7%), starting 4 hours after the infusion of verteporfin, and resolved within 72 hours after PDT. A total of 8 patients (2.9%; 95% CI, 1.3%-5.7%) reported an acute severe visual acuity decrease of at least 4 Early Treatment Diabetic Retinopathy Study lines occurring within 7 days of treatment.

Conclusions  Complications associated with PDT are uncommon, but there were limitations of retrospective studies for identifying safety problems. Complications like acute severe visual events may occur in about 3% of patients. We believe that this risk is outweighed by the benefits of PDT on visual function in most patients.


Author Affiliations: Departments of Ophthalmology, University Eye Hospital, Bern, Switzerland (Drs Schnurrbusch and Wolf), and University Hospital Leipzig, Leipzig, Germany (Drs Jochmann and Einbock).


RELATED LETTER

Acute Respiratory Distress Due to Verteporfin Infusion for Photodynamic Therapy
Maurizio Fossarello and Enrico Peiretti
Arch Ophthalmol. 2006;124(10):1509-1510.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Acute Respiratory Distress Due to Verteporfin Infusion for Photodynamic Therapy
Fossarello and Peiretti
Arch Ophthalmol 2006;124:1509-1510.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.